(Q34949268)

English

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

phase II clinical trial

0 references

0 references

author name string

Robert S Rosenson

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Colin Hislop

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Daniel McConnell

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michael Elliott

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Yuri Stasiv

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Nan Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

David D Waters

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PLASMA Investigators

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

373

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

9664

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

649-658

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

The phospholipase A2 superfamily and its group numbering system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretory group II phospholipase A2 in human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipolysis of LDL by Human Secretory Phospholipase A 2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of secretory phospholipases in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization and determinants of an electronegatively charged low-density lipoprotein in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960403-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60403-7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34949268&oldid=1994347612"